Monoclonal Antibodies and Immune Therapies for Adult Precursor B-Acute Lymphoblastic Leukemia

Highlights • Immunotherapies and antibody-drug conjugates aim to improve efficacy and reduce toxicity in treatment of adult B-ALL. • CD19 and CD22 are internalized B cell surface markers expressed nearly universally in B lymphocytes. • CAR T cells are a highly promising new agent with response rates...

Full description

Saved in:
Bibliographic Details
Published inImmunology letters Vol. 172; pp. 113 - 123
Main Authors Sikaria, Swati, Aldoss, Ibrahim, Akhtari, Mojtaba
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.04.2016
Subjects
Acute lymphoblastic leukemia
Adult
Allergy and Immunology
Antibodies, Bispecific - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antigens, Differentiation - immunology
Cancer Vaccines - immunology
Clinical Trials as Topic
Humans
Immunotherapy
Immunotherapy - methods
Immunotoxins - therapeutic use
Leukemia
Monoclonal antibodies
Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Precursor Cells, B-Lymphoid - pathology
Protein Engineering
Receptors, Antigen, T-Cell - genetics
Rituximab - therapeutic use
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
leukemia
acute lymphoblastic leukemia
immunotherapy
monoclonal antibodies
Monoclonal antibodies
Acute lymphoblastic leukemia
Immunotherapy
Leukemia
Online AccessGet full text

Cover

More Information
Summary:Highlights • Immunotherapies and antibody-drug conjugates aim to improve efficacy and reduce toxicity in treatment of adult B-ALL. • CD19 and CD22 are internalized B cell surface markers expressed nearly universally in B lymphocytes. • CAR T cells are a highly promising new agent with response rates as high as 90% even in patients who are heavily pre-treated, including post-allogeneic transplant and after prior treatment with blinatumomab. • Blinatumomab has proven efficacy in relapsed or primary refractory pre-B ALL with response rates of 34–80% depending on degree of pre-treatment. • Inotuzumab is a CD22 antibody conjugated to calicheamicin with a response rate around 58% in relapsed/refractory B-ALL with responses typically seen after the first cycle, and may have a role in elderly patients as well.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0165-2478
1879-0542
DOI:10.1016/j.imlet.2016.02.014